We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
BPC-157 is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most BPC-157 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1997–2025 with a typical study size of 17 participants.
Based on 12 studies · 29 total participants
Confidence
LowBy outcome
The current evidence for BPC-157 is insufficient to assign an evidence score, based on 12 indexed studies. A synthetic 15-amino-acid research peptide (a fragment of a protein found in gastric juice) widely promoted online for tendon, gut and wound healing. Honest appraisal: essentially the entire evidence base is preclinical — rat studies and cell experiments from a small number of research groups. There are NO published randomized controlled trials in humans; the only human reports are a couple of tiny, uncontrolled case series. It is not a dietary supplement: it is sold 'for research use only' and the FDA has effectively barred it from compounding. Representative study: PMID 40756949.
The commonly studied dose of BPC-157 is No validated human dose exists. BPC-157 has never been dose-established in a published human trial. Anecdotal non-clinical protocols circulated online use roughly 200-500 mcg/day subcutaneously, but these figures have no clinical basis, no safety validation, and should not be read as a recommendation.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Notable regimens that report including BPC-157 — documented, not endorsed.
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
BPC-157 (Body Protection Compound 157)
A synthetic 15-amino-acid research peptide (a fragment of a protein found in gastric juice) widely promoted online for tendon, gut and wound healing. Honest appraisal: essentially the entire evidence base is preclinical — rat studies and cell experiments from a small number of research groups. There are NO published randomized controlled trials in humans; the only human reports are a couple of tiny, uncontrolled case series. It is not a dietary supplement: it is sold 'for research use only' and the FDA has effectively barred it from compounding.
Scores very low because human evidence is essentially absent — the entire base is rat and cell studies from a few groups plus two tiny uncontrolled case series, with no randomized controlled human trials and no regulated product.
BPC-157 ('Body Protection Compound 157') is a synthetic pentadecapeptide (15 amino acids, sequence GEPPPGKPADDAGLV) derived from a partial sequence of a protein isolated from human gastric juice. It is marketed online as a 'healing peptide' for tendon, ligament, muscle and gastrointestinal injuries.
The honest evidence picture is that almost all of the literature is preclinical: rat models of injury (Achilles tendon transection, gastric/intestinal ulceration, fistulas, vascular occlusion, spinal cord and brain injury) and a smaller number of in-vitro cell experiments, produced largely by a single Croatian research group and a handful of collaborators.
Across these animal models BPC-157 is reported to accelerate healing and to be very well tolerated (the authors repeatedly note a lethal dose was not reached). However, the peptide has essentially never been tested in a published randomized controlled human trial.
The only human data are tiny, uncontrolled case series — a retrospective chart review of intra-articular injection for knee pain (17 patients) and a 12-patient pilot of intravesical injection for interstitial cystitis — neither of which has a control group, blinding, or independent replication, so they cannot establish efficacy.
Critically, BPC-157 is NOT a regulated dietary supplement. It is sold 'for research use only', purity and sterility of injectable product are unverified, and in 2023 the US FDA placed it on the 503A 'category 2' bulk-substances list, effectively barring compounding pharmacies from using it.
Its strongly pro-angiogenic mechanism (VEGFR2-Akt-eNOS-NO signalling) also raises an unstudied theoretical concern about promoting tumor vascular growth. Overall evidence is Emerging and human safety and efficacy are unproven.
In preclinical models BPC-157 is described as a potent angiomodulatory agent, promoting new blood-vessel formation and 'recruiting' collateral vessels around occluded ones, acting through VEGF/VEGFR2 and nitric-oxide signalling. All evidence is from animal and cell studies; this pro-vascular action is also the basis of a theoretical, unstudied tumor-growth concern.
Rat studies report BPC-157 interacts with the L-arginine/L-NAME nitric-oxide system, influencing gastric mucosal protection, blood-pressure regulation and vascular responses. This is a proposed preclinical mechanism, not a validated human target.
In cultured rat Achilles-tendon fibroblasts BPC-157 increased cell outgrowth, survival under oxidative stress, and migration, with dose-dependent phosphorylation of FAK and paxillin. This is an in-vitro mechanism proposed to underlie tendon healing; it has not been shown to translate to humans.
BPC-157 is framed by its authors as a mediator of Robert's gastrointestinal 'cytoprotection' that also acts along the gut-brain and brain-gut axis, with reported neuroprotective effects in rat stroke, brain- and spinal-cord-injury models. Preclinical and mechanistic only.
How BPC-157 works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated human dose exists. BPC-157 has never been dose-established in a published human trial. Anecdotal non-clinical protocols circulated online use roughly 200-500 mcg/day subcutaneously, but these figures have no clinical basis, no safety validation, and should not be read as a recommendation.
Can be taken without food
| Form | Type |
|---|---|
| 💊None — no form has validated human efficacy or an approved standard | Recommended |
BPC-157 is a research chemical, not an approved drug or dietary supplement. There is no quality-controlled, regulator-sanctioned product.
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Not required
Note: No evidence-based timing exists. Anecdotal injectable protocols vary widely; none are validated.
Dose-response data unavailable. The current published research for BPC-157 does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
There are no published randomized controlled trials of BPC-157 in humans. Every claimed benefit below comes from rat models, cell experiments, or tiny uncontrolled case series, none of which can establish that it works in people.
Rat studies and cell experiments report accelerated healing of transected Achilles tendon and other soft-tissue and muscle injuries via increased fibroblast outgrowth, survival and migration. Unproven in humans.
In rats BPC-157 is reported to protect the stomach and intestine against alcohol and NSAID injury, stabilize intestinal permeability ('leaky gut'), and heal gastrointestinal fistulas and anastomoses. Related sequence PL-14736 was studied in inflammatory bowel disease. Human ulcer/IBD efficacy is not established.
Rat models report BPC-157 both prevents/reverses thrombosis and reduces bleeding and thrombocytopenia after amputation in animals treated with heparin, warfarin or aspirin, attributed to angiogenesis and 'collateral pathway' activation. Not tested in humans.
Rat stroke, spinal-cord-compression and schizophrenia/dopamine models report functional recovery with BPC-157. Entirely preclinical; no human neurological data.
Because its proposed mechanism is strong angiogenesis (new blood-vessel growth), there is an unstudied theoretical risk it could support tumor vascularization. This has not been evaluated in humans and is a reason for caution, especially with any history of cancer.
Avoid — never studied in pregnancy or lactation.
Avoid — strong pro-angiogenic mechanism raises an unstudied theoretical tumor-growth risk.
Avoid — BPC-157 is an unapproved, non-permitted experimental substance and its status in sport is problematic.
Avoid or use only under medical supervision — animal data show effects on clotting and platelets.
Rat studies show BPC-157 alters bleeding, clotting and platelet counts in animals given these drugs. The direction and clinical relevance in humans are unknown, so any combination with blood thinners is unpredictable and warrants caution.
Tip: There is no safe verified product; risk stems from unregulated 'research use only' sourcing rather than the peptide itself.
Tip: No human safety data exist; absence of reported harm is not evidence of safety.
Timing is flexible for BPC-157 — consistent daily use matters more than the time of day. There is no evidence-based dosing schedule because no human pharmacokinetic or efficacy trial has established one.
BPC-157 should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-related risks (infection, abscess, contamination from non-sterile product), unknown long-term effects. Use caution if any of these apply to you: Pregnancy and breastfeeding — never studied; avoid entirely; Active cancer or history of cancer — theoretical angiogenesis/tumor-growth concern, never evaluated in humans; Any use expecting a regulated, quality-controlled medicine — BPC-157 is a research chemical, not an approved drug or supplement.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Review-level work proposes BPC-157 counteracts disturbances of dopamine, serotonin, glutamate, GABA, adrenergic and acetylcholine systems in rats. These are hypothesised, indirect interactions inferred from animal models, not demonstrated receptor pharmacology in humans.